The present invention provides a hyaluronic acid derivative having a steryl group introduced therein, wherein a ratio Mw/Mn of a weight-average molecular weight Mw to a number-average molecular weight Mn of the hyaluronic acid derivative is 1.11 or more and 10.0 or less.

The present invention is directed to nanofilaments for polymer brushes, to polymer brushes comprising the nanofilaments and methods of making the same. In particular, the invention provides water soluble nanofilaments which may be grafted to a surface and which may be functionalised with (bio)molecules.

A hyaluronic acid-based aqueous gel including crosslinked hyaluronic acid and from 30 to 70% by mass with respect to the total mass of hyaluronic acid, of a water-soluble hyaluronic acid. A method for preparing an aqueous gel having at least a crosslinked hyaluronic acid and at least an uncrosslinked hyaluronic acid. Also an aqueous gel obtainable by the method compositions, a cosmetic and/or dermatological composition including the aqueous gels, and a kit comprising a pre-filled syringe comprising the aqueous gel or said composition. These gels and compositions are useful in particular for treating an alteration in the surface appearance of the skin and/or for augmenting and/or filling soft tissue.

The present invention relates to a hyaluronic acid-based hydrogel which is a hyaluronic acid-peptide crosslinked body crosslinked using a peptide crosslinking agent. More specifically, the present invention relates to a hyaluronic acid-based hydrogel and a method for producing same, wherein a crosslinked body having novel physical properties is obtained using a relatively small amount of a crosslinking agent that forms peptide bonds, unlike conventional crosslinking agents, and the hyaluronic acid-based hydrogel has the advantages of: being safe and having few side effects; the physical properties of a filler being adjustable according to the amount of peptide crosslinking; and having a high elasticity ratio.

Systems, methods, and kits are described for repairing a fibrocartilage defect in a subject. The fibrocartilage defect is contacted with a first composition containing an oxidized and methacrylated glycosaminoglycan to form an imine bond between the glycosaminoglycan and the fibrocartilage defect, thereby coating the fibrocartilage defect with the glycosaminoglycan. The fibrocartilage defect coated with the glycosaminoglycan is then contacted with a mixture of a pre-polymer hydrogel composition containing a first crosslinking unit that, when polymerized, is capable of bonding to methacrylate and a hydrogel polymerization initiator composition, thereby forming a hydrogel that is covalently bonded to the glycosaminoglycan through methacrylate.

The present invention provides a hydrogel platform using, as a substrate, hyaluronic acid (HA) conjugated to a pyrogallol (PG) moiety. The HA-PG conjugate of the present invention can be rapidly crosslinked by two different methods, in each of which an oxidizing agent is used or a pH is adjusted. The hydrogel of the present invention can not only have excellent biocompatibility, but also can have efficiently controlled physical characteristics such as a crosslinking rate, elasticity, and adhesive strength, depending on each crosslinking method. On the basis of such excellent stability and functionality, the hydrogel of the present invention can be used in various fields including drug delivery, biopharmaceutical materials such as a wound healing agent or anti-adhesive agent, medicines, and cosmetic products.

An industrial synthesis process of a hyaluronic acid-paclitaxel conjugate obtained by introducing the 4-bromobutyric acid spacer/linker between the hyaluronic acid and the paclitaxel, said conjugate being characterized by a high purity, the related pharmaceutical compositions for use in the treatment of multiple cancer forms are described.

The invention relates to a hydrogel product comprising glycosaminoglycan molecules as the swellable polymer, wherein the glycosaminoglycan molecules are covalently crosslinked via crosslinks comprising a spacer group selected from the group consisting of di-, tri-, tetra-, and oligosaccharides.

HA-paclitaxel conjugate for use in the loco-regional treatment of the mesothelioma, i.e., the malignant pleural mesothelioma, pericardial mesothelioma and peritoneal mesothelioma, preferably malignant pleural mesothelioma, and relative pharmaceutical compositions are described.

The present invention relates to cross-linked polymers (e.g., hydrogels) including hyaluronan polymer and multimeric cross-linker for treating disorders (e.g., retinal detachment or osteoarthritis), for use in screening models (e.g., in vitro cell culture system), or for cell transplantation (e.g., in vivo cell delivery).